CTOs on the Move

Bausch Health Companies

www.ir.bauschhealth.com

 
Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Canada.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.

Stiefel, a GSK Company

Stiefel, a GSK Company is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shop Phocus

Phocus is a company that provides a product to fuel creativity and elevate the mind.

Cadila Pharmaceuticals - CPL

Cadila Pharmaceuticals - CPL, Inc. is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.